Citadel Advisors LLC Buys New Stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX)

Citadel Advisors LLC purchased a new position in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned about 0.31% of BioRestorative Therapies at the end of the most recent quarter.

BioRestorative Therapies Trading Up 6.4%

NASDAQ BRTX opened at $2.00 on Friday. The company has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $1.78. The stock has a market cap of $15.01 million, a P/E ratio of -1.31 and a beta of 76.75. BioRestorative Therapies, Inc. has a 12-month low of $1.21 and a 12-month high of $2.55.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.24). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.38 million. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. As a group, sell-side analysts forecast that BioRestorative Therapies, Inc. will post -1.43 earnings per share for the current year.

BioRestorative Therapies Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.